9/16/2025

iRhythm remains a high-quality, high-growth medtech company with strong GM and revenue momentum, but capital intensity persists. See why IRTC stock is a hold.

Source: SeekingAlpha

9/12/2025

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 11.28% (gross) and 11.02% (net), compared to the Russell 2000 Growth Index by 11.97%. Equities posted double-digit returns in the second […]

Source: Yahoo

9/11/2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Source: Yahoo

9/9/2025

Discover iRhythm's growth, tech, & market strategy from the Morgan Stanley Healthcare

Source: SeekingAlpha

9/2/2025

iRhythm's AMALFI trial shows its Zio monitoring service boosts AF detection and speeds diagnosis, strengthening its edge in cardiac care.

Source: Yahoo

9/1/2025

What a time it’s been for iRhythm. In the past six months alone, the company’s stock price has increased by a massive 54.5%, reaching $168.51 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Source: Yahoo

8/29/2025

Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United Kingdom (UK).A remote screening strategy with the Zio LTCM service led to an increase in AFib

Source: Yahoo

8/22/2025

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global markets saw an incredible but volatile quarter in the second quarter, shifting from deep declines to strong gains. In the quarter, its Investor Class fund ARTSX returned 7.30%, Advisor […]

Source: Yahoo

8/21/2025

iRhythm Technologies recently announced the publication of the AVALON study in the American Journal of Managed Care, which found that the Zio long-term continuous monitoring service led to faster cardiac arrhythmia diagnoses, fewer cardiovascular events, reduced healthcare utilization, and lower total healthcare costs compared to other ambulatory cardiac monitoring options in a large real-world setting. This comprehensive, independently analyzed study provides strong comparative evidence...

Source: Yahoo

8/20/2025

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, Se

Source: Yahoo

8/20/2025

iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the best Russell 2000 stocks to buy now. On July 31, the company’s management held an earnings call in which they hailed the records set in Q2 2025, as well as earnings beats. During the quarter, iRhythm’s revenue reached $186.7 million, a 26.1% year-over-year increase. The result beat […]

Source: Yahoo

8/18/2025

In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service’s value across patient populations and payer segments. SAN FRANCISCO, Aug. 18, 2025 (

Source: Yahoo

8/13/2025

Source: SeekingAlpha

8/13/2025

Global markets turned in an impressive but volatile Q2, swinging from double-digit declines to double-digit gains. Click here to read more.

Source: SeekingAlpha

8/13/2025

Tempus AI's soaring Q2 revenues, margin gains and near-EBITDA breakeven position it as a fast-rising force in precision medicine.

Source: Yahoo

8/13/2025

Source: SeekingAlpha

8/13/2025

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 26.1% year on year to $186.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.32 per share was 32.5% above analysts’ consensus estimates.

Source: Yahoo

8/13/2025

iRhythm’s second quarter results were driven by accelerating growth in its core long-term cardiac monitoring business, expanded adoption of the Zio AT product, and increased contributions from innovative channel partnerships. Management attributed the strong revenue growth to record new account openings, particularly among integrated delivery networks, and highlighted new partnerships, such as with Lucem Health, that leverage artificial intelligence to identify at-risk patients earlier. CEO Quen

Source: Yahoo

8/2/2025

iRhythm Technologies ( NASDAQ:IRTC ) Second Quarter 2025 Results Key Financial Results Revenue: US$186.7m (up 26% from...

Source: Yahoo

8/1/2025

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 18% in the morning session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year revenue forecast.

Source: Yahoo